NASDAQ
27.01.26 | 22:00
4,020 US-Dollar
-0,99 % -0,040
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.01. | Why Shattuck Labs Stock Soared in December | 1 | The Motley Fool | ||
| 15.12.25 | Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 01.12.25 | Shattuck Labs stock rating upgraded to Buy by H.C. Wainwright | 2 | Investing.com | ||
| 07.11.25 | Shattuck Labs GAAP EPS of -$0.14 | 1 | Seeking Alpha | ||
| 06.11.25 | Shattuck Labs, Inc.: Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 193 | GlobeNewswire (Europe) | -First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers - - Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 - - Appointments... ► Artikel lesen | |
| 06.11.25 | Shattuck Labs, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | Shattuck Labs, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.10.25 | Shattuck Labs stellt auf UEG-Kongress innovativen Ansatz zur IBD-Behandlung vor | 1 | Investing.com Deutsch | ||
| 02.10.25 | Shattuck Labs, Inc.: Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel | 2 | GlobeNewswire (USA) | ||
| 26.08.25 | Shattuck Labs closes $103 million private placement led by OrbiMed | 2 | Investing.com | ||
| 26.08.25 | Shattuck Labs, Inc.: Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 26.08.25 | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.08.25 | H.C. Wainwright maintains Neutral rating on Shattuck Labs stock as FDA clears IND | 2 | Investing.com | ||
| 21.08.25 | Shattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease | 387 | GlobeNewswire (Europe) | - SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases - - The Company... ► Artikel lesen | |
| 14.08.25 | Leerink Partners senkt Kursziel für Shattuck Labs auf 2 $ | 1 | Investing.com Deutsch | ||
| 14.08.25 | Shattuck Labs stock price target lowered to $2 by Leerink Partners | 1 | Investing.com | ||
| 14.08.25 | Shattuck Labs GAAP EPS of -$0.24 in-line | 2 | Seeking Alpha | ||
| 14.08.25 | Shattuck Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08.25 | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUREXONE BIOLOGIC | 0,431 | +5,90 % | NurExone Biologic: Fortschritte in Milliardenmarkt für Rückenmarksverletzungen | ||
| ONCO-INNOVATIONS | 0,655 | +1,55 % | Onco-Innovations Limited: Onco-Innovations Announces Private Placement | Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / January 23, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H... ► Artikel lesen | |
| FRACTYL HEALTH | 2,115 | 0,00 % | Fractyl Health und BioAge Labs: Weitere Top-Renditen im NBC! | Mit Fractyl Health und BioAge Labs blicken Mitglieder des No Brainer Club auf die nächsten großen Renditebringer in ihren Depots. Beide Empfehlungen konnten sich in den letzten Monaten im Wert verdoppeln.... ► Artikel lesen | |
| QIAGEN | 45,485 | -2,04 % | Aktien Frankfurt Ausblick: Kleines Minus im Dax erwartet - Qiagen weiter stark | FRANKFURT (dpa-AFX) - Der deutsche Aktienmarkt bleibt auch am Mittwoch im Korrekturmodus. Nachdem sich zuletzt die Unsicherheit wegen der Zoll-Politik von US-Präsident Donald Trump wieder verstärkt... ► Artikel lesen | |
| CG ONCOLOGY | 55,10 | +3,38 % | What Analysts Are Saying About CG Oncology Stock | ||
| PRAXIS PRECISION MEDICINES | 314,75 | +7,04 % | Piper Sandler bekräftigt "Overweight"-Rating für Praxis Precision Medicines | ||
| ADMA BIOLOGICS | 16,580 | 0,00 % | ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? | ||
| ARCELLX | 68,51 | 0,00 % | Arcellx präsentiert Daten zu Anito-Cel auf den Tandem Meetings 2026 | ||
| ERASCA | 10,500 | 0,00 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| NUVALENT | 106,45 | 0,00 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 89,51 | -0,07 % | Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It | ||
| COGENT BIOSCIENCES | 38,500 | +1,69 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,600 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 15,470 | 0,00 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,64 | +0,01 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen |
Das Unternehmen SHATTUCK LABS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,99 % bei einem Aktienkurs von 4,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.